View all Gertz J publications in the NIH PubMed database

Selected Publications

Estrogen-induced chromatin looping changes identify a subset of functional regulatory elements.
Abewe H, Richey A, Vahrenkamp JM, Ginley-Hidinger M, Rush CM, Kitchen N, Zhang X, Gertz J.  Genome Res. 2025 Mar 18;35(3):393-403. doi: 10.1101/gr.279699.124. PubMed PMID: 40032586; PubMed Central PMCID: PMC11960465

Cis-regulatory control of transcriptional timing and noise in response to estrogen.
Ginley-Hidinger M, Abewe H, Osborne K, Richey A, Kitchen N, Mortenson KL, Wissink EM, Lis J, Zhang X, Gertz J.  Cell Genom. 2024 May 8;4(5):100542. doi: 10.1016/j.xgen.2024.100542. Epub 2024 Apr 24. PubMed PMID: 38663407; PubMed Central PMCID: PMC11099348.

Allele-Specific Gene Regulation, Phenotypes, and Therapeutic Vulnerabilities in Estrogen Receptor Alpha-Mutant Endometrial Cancer. 
Blanchard Z, Rush CM, Arnesen S, Vahrenkamp JM, Rodriguez AC, Jarboe EA, Brown C, Chang MEK, Flory MR, Mohammed H, Modzelewska K, Lum DH, Gertz J. Mol Cancer Res. 2023 Oct 2;21(10):1023-1036. doi: 10.1158/1541-7786.MCR-22-0848. PubMed PMID: 37363949.

Estrogen receptor alpha mutations regulate gene expression and cell growth in breast cancer through microRNAs.
Arnesen S, Polaski JT, Blanchard Z, Osborne KS, Welm AL, O'Connell RM, Gertz J.  NAR Cancer. 2023 Jun;5(2):zcad027. doi: 10.1093/narcan/zcad027. eCollection 2023 Jun. PubMed PMID: 37275275; PubMed Central PMCID: PMC10233889.

Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line.
Rush CM, Blanchard Z, Polaski JT, Osborne KS, Osby K, Vahrenkamp JM, Yang CH, Lum DH, Hagan CR, Leslie KK, Pufall MA, Thiel KW, Gertz J. Sci Rep. 2022 Nov 17;12(1):19731. doi: 10.1038/s41598-022-24211-8. PubMed PMID: 36396974; PubMed Central PMCID: PMC9672046.

Estrogen Receptor Alpha Mutations in Breast Cancer Cells Cause Gene Expression Changes through Constant Activity and Secondary Effects.
Arnesen S, Blanchard Z, Williams MM, Berrett KC, Li Z, Oesterreich S, Richer JK, Gertz J.Cancer Res. 2021 Feb 1;81(3):539-551. doi: 10.1158/0008-5472.CAN-20-1171. Epub 2020 Nov 12.

Regulatory sharing between estrogen receptor α bound enhancers.
Carleton JB, Ginley-Hidinger M, Berrett KC, Layer RM, Quinlan AR, Gertz J. Nucleic Acids Res. 2020 Jul 9;48(12):6597-6610. doi: 10.1093/nar/gkaa454.

ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells.
Rodriguez AC, Vahrenkamp JM, Berrett KC, Clark KA, Guillen KP, Scherer SD, Yang CH, Welm BE, Janát-Amsbury MM, Graves BJ, Gertz J.Cancer Res. 2020 Mar 15;80(6):1234-1245. doi: 10.1158/0008-5472.CAN-19-1382. Epub 2020 Feb 11.

FFPEcap-seq: a method for sequencing capped RNAs in formalin-fixed paraffin-embedded samples.
Vahrenkamp JM, Szczotka K, Dodson MK, Jarboe EA, Soisson AP, Gertz J. Genome Res. 2019 Nov;29(11):1826-1835. doi: 10.1101/gr.249656.119. Epub 2019 Oct 24.

Sufficiency analysis of estrogen responsive enhancers using synthetic activators.
Ginley-Hidinger M, Carleton JB, Rodriguez AC, Berrett KC, Gertz J. Life Sci Alliance. 2019 Sep 30;2(5):e201900497. doi: 10.26508/lsa.201900497. Print 2019 Oct.

Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer.
Blanchard Z, Vahrenkamp JM, Berrett KC, Arnesen S, Gertz J. Genome Res. 2019 Sep;29(9):1429-1441. doi: 10.1101/gr.244780.118. Epub 2019 Jul 30.

Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions.
Rodriguez AC, Blanchard Z, Maurer KA, Gertz J.
Horm Cancer. 2019 Jun;10(2-3):51-63. doi: 10.1007/s12672-019-0358-9. Epub 2019 Feb 2.